FDA Draft Guidance On ANDA Impurities Conforms to ICH Standard
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms should use stability studies, chemical development studies and routine batch analysis to test for impurities, the guidance says.
You may also be interested in...
Revised Generic Drug Substance Impurities Guidance To Be Issued By FDA
Assuming the Office of Chief Counsel does not need to review the guidance, FDA plans to release it “in very short order.” The agency also has plans to replace the existing drug product impurities draft guidance.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.